VTP-300 shows durable HBsAg reductions in chronic hepatitis B; no serious adverse events

Barinthus Biotherapeutics plc.

Updated interim data (n=39) shows VTP-300 as monotherapy or +nivolumab had no treatment-related SAEs; 2 mild transaminitis cases.
In monotherapy, 3 patients with baseline HBsAg <50 IU/mL had 0.7-1.4 log10 declines durable up to 8 months.
Combination group (8 patients) had mean HBsAg reduction >1 log10 at 6 months, persisting to 1.15 log10 at 8 months.
Robust T cell response with marked CD8+ predominance observed; enrollment complete at 55 patients.
Updated interim analysis for all patients at 6-month follow-up expected end of 2022; new trial dosing expected Q3 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.